Side-by-side · Research reference

ChonlutenvsDSIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BHuman-MechanisticAUTO-DRAFTED8/36 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

01Mechanism of Action

Parameter

Chonluten

DSIP

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Feedback intact?

—

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

DSIP

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

Once daily, pre-sleep

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Human-mechanistic + early clinicalSchneider 1986

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

8–12 weeks per cycle

Clinical validation

None (PubMed indexed)

—

Standard dose

—

100–200 mcg SQ pre-sleepSchneider 1986

Lower / starter dose

—

50 mcg pre-sleep

Reconstitution

—

Bacteriostatic water

Timing

—

30–60 min pre-sleep

Half-life

—

Short plasma; CNS effects last hours

04Side Effects & Safety

Parameter

Chonluten

DSIP

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Injection site reaction

—

Mild irritation

Drowsiness

—

Expected effect (intentional)

Vivid dreams

—

Anecdotally reported

Long-term safety

—

Limited modern RCT data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

05Administration Protocol

Parameter

Chonluten

DSIP

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Add 1–2 mL bacteriostatic water to vial.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

SQ — abdomen. Rotate sites.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

30–60 min pre-sleep.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

29–31G insulin syringe.